{"created":"2023-05-15T16:36:27.815245+00:00","id":9510,"links":{},"metadata":{"_buckets":{"deposit":"7a31f62b-20ee-4346-b649-8c63be24dc68"},"_deposit":{"created_by":2,"id":"9510","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"9510"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00009510","sets":["8:9"]},"author_link":["38400","38396","38398","38395","38403","38401","38397","38402","38399","38404"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-07-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageEnd":"940","bibliographicPageStart":"935","bibliographicVolumeNumber":"83","bibliographic_titles":[{"bibliographic_title":"Journal of Neurology, Neurosurgery & Psychiatry"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objective: We developed an assay that detects autoantibodies against the main immunogenic region (MIR) located at the extracellular end of the nicotinic acetylcholine receptor (AChR) a subunit, and investigated its clinical relevance in myasthenia gravis (MG). Methods: In this retrospective cohort study, we measured MIR antibody (Ab) titres in sera obtained before treatment and analysed their associations with clinical parameters in 102 MG patients from two neurological centres. MIR Ab titres were determined using a modified competition immunoprecipitation assay in the presence or absence of monoclonal antibody 35. Results: 11 of 23 (47.8%) ocular type and 66 of 72 (91.7%) generalised type MG patients were positive for the presence of MIR Abs, defined as a titre >16.8% (3 SDs above the mean for 70 healthy controls). A significantly higher MIR Ab titre (p<0.001) was shown in generalised type (47.9±19.2%) rather than in ocular type MG patients (16.4±8.4%). Bivariate regression analysis using both titre levels of MIR Ab and routine AChR binding Ab as variables revealed MIR Abs to be an exclusive indicator positively associated with disease severity (Myasthenia Gravis Foundation of America classification, p<0.0001; Quantitative MG score, p=0.008), the presence of bulbar symptoms (p<0.0001) and thymoma (p=0.016), and negatively associated with ocular MG (p<0.0001). Conclusions: MIR Ab titre levels show much better correlations with factors related to disease severity compared with AChR binding Ab titres. The MIR Ab assay may be useful for predicting MG symptom severity, especially for discriminating between ocular and generalised types of MG.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Journal of Neurology, Neurosurgery & Psychiatry, 83(9), pp.935-940; 2012","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BMJ Publishing Group"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1136/jnnp-2012-302705","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2012 by the BMJ Publishing Group Ltd. All rights reserved."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00223050","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Masuda, Tomoko"}],"nameIdentifiers":[{"nameIdentifier":"38395","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Motomura, Masakatsu"}],"nameIdentifiers":[{"nameIdentifier":"38396","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Utsugisawa, Kimiaki"}],"nameIdentifiers":[{"nameIdentifier":"38397","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagane, Yuriko"}],"nameIdentifiers":[{"nameIdentifier":"38398","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakata, Ruka"}],"nameIdentifiers":[{"nameIdentifier":"38399","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tokuda, Masahiro"}],"nameIdentifiers":[{"nameIdentifier":"38400","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fukuda, Taku"}],"nameIdentifiers":[{"nameIdentifier":"38401","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimura, Toshiro"}],"nameIdentifiers":[{"nameIdentifier":"38402","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujihata, Mitsuhiro"}],"nameIdentifiers":[{"nameIdentifier":"38403","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"38404","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-22"}],"displaytype":"detail","filename":"JNNP83_935.pdf","filesize":[{"value":"272.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JNNP83_935.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/9510/files/JNNP83_935.pdf"},"version_id":"d7a3de91-6e08-4d1e-933e-b648fada657a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"autoantibody","subitem_subject_scheme":"Other"},{"subitem_subject":"main immunogenic region autoantibody","subitem_subject_scheme":"Other"},{"subitem_subject":"monoclonal antibody","subitem_subject_scheme":"Other"},{"subitem_subject":"monoclonal antibody 35","subitem_subject_scheme":"Other"},{"subitem_subject":"nicotinic receptor","subitem_subject_scheme":"Other"},{"subitem_subject":"nicotinic receptor alpha","subitem_subject_scheme":"Other"},{"subitem_subject":"unclassified drug","subitem_subject_scheme":"Other"},{"subitem_subject":"adult","subitem_subject_scheme":"Other"},{"subitem_subject":"antibody blood level","subitem_subject_scheme":"Other"},{"subitem_subject":"antibody detection","subitem_subject_scheme":"Other"},{"subitem_subject":"antibody titer","subitem_subject_scheme":"Other"},{"subitem_subject":"antigen binding","subitem_subject_scheme":"Other"},{"subitem_subject":"article","subitem_subject_scheme":"Other"},{"subitem_subject":"bulbar paralysis","subitem_subject_scheme":"Other"},{"subitem_subject":"controlled study","subitem_subject_scheme":"Other"},{"subitem_subject":"disease classification","subitem_subject_scheme":"Other"},{"subitem_subject":"disease severity","subitem_subject_scheme":"Other"},{"subitem_subject":"female","subitem_subject_scheme":"Other"},{"subitem_subject":"generalized myasthenia gravis","subitem_subject_scheme":"Other"},{"subitem_subject":"human","subitem_subject_scheme":"Other"},{"subitem_subject":"immunoprecipitation","subitem_subject_scheme":"Other"},{"subitem_subject":"major clinical study","subitem_subject_scheme":"Other"},{"subitem_subject":"male","subitem_subject_scheme":"Other"},{"subitem_subject":"myasthenia gravis","subitem_subject_scheme":"Other"},{"subitem_subject":"ocular myasthenia gravis","subitem_subject_scheme":"Other"},{"subitem_subject":"prediction","subitem_subject_scheme":"Other"},{"subitem_subject":"priority journal","subitem_subject_scheme":"Other"},{"subitem_subject":"receptor binding","subitem_subject_scheme":"Other"},{"subitem_subject":"retrospective study","subitem_subject_scheme":"Other"},{"subitem_subject":"scoring system","subitem_subject_scheme":"Other"},{"subitem_subject":"thymoma","subitem_subject_scheme":"Other"},{"subitem_subject":"Animals","subitem_subject_scheme":"Other"},{"subitem_subject":"Antibodies","subitem_subject_scheme":"Other"},{"subitem_subject":"Monoclonal","subitem_subject_scheme":"Other"},{"subitem_subject":"Autoantibodies","subitem_subject_scheme":"Other"},{"subitem_subject":"Biological Markers","subitem_subject_scheme":"Other"},{"subitem_subject":"Middle Aged","subitem_subject_scheme":"Other"},{"subitem_subject":"Myasthenia Gravis","subitem_subject_scheme":"Other"},{"subitem_subject":"Rats","subitem_subject_scheme":"Other"},{"subitem_subject":"Rats, Inbred Lew","subitem_subject_scheme":"Other"},{"subitem_subject":"Receptors, Nicotinic","subitem_subject_scheme":"Other"},{"subitem_subject":"Retrospective Studies","subitem_subject_scheme":"Other"},{"subitem_subject":"Severity of Illness Index","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-12-27"},"publish_date":"2012-12-27","publish_status":"0","recid":"9510","relation_version_is_last":true,"title":["Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T01:44:13.998719+00:00"}